Article citationsMore>>
Verma, S., Miles, D., Gianni, L., Krop, I.E., Welslau, M., Baselga, J., Pegram, M., Oh, D.Y., Diéras, V., Guardino, E., Fang, L., Lu, M.W., Olsen, S., Blackwell, K., for the EMILIA Study Group (2012) Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine, 367, 1783-1791.
https://doi.org/10.1056/NEJMoa1209124
has been cited by the following article:
-
TITLE:
Impressive Objective Response to Nab-Paclitaxel plus Trastuzumab as Fifth Line Therapy in an Elderly HER-2 Positive Breast Cancer Patient
AUTHORS:
Maria Rosaria Valerio, Chiara Ancona, Antonella Marchese, Vittorio Gebbia
KEYWORDS:
Nab-Paclitaxel, Trastuzumab, HER-2, Metastasis, Breast Cancer
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.8 No.11,
November
16,
2017
ABSTRACT: Background: Agent targeting HER-2 pathway
plus chemotherapy has represented a major
progress in the management of patients with breast cancer. However, the role of late-line treatment in heavily
pretreated patients is still largely unclear. In the last decade, nab-paclitaxel has shown significant activity
and good toxicity profile in metastatic breast cancer. Case Presentation: We report the case of a 76-year-old Caucasian woman
with metastatic HER-2 positive ductal infiltrating breast carcinoma treated
with a combination of weekly nab-paclitaxel and trastuzumab as fifth-line
therapy. She had previously received first-line paclitaxel and trastuzumab,
second-line vinorelbine and trastuzumab, third-line TDM1 and fourth-line oral
capecitabine and lapatinib. Clinical and radiological staging showed
progression at bone, skin and soft-tissue. The patient received weekly
nab-paclitaxel plus trastuzumab. Massive objective response was clinically and
PET documented which lasted 8 months. Tolerance to treatment was fairly good as
well as cardiac safety. Conclusion: To the best of our knowledge, this
is the first reported case of efficacy of nab-paclitaxel in combination with
trastuzumab as fifth-line of treatment in a patient with metastatic HER-2
positive breast cancer.
Related Articles:
-
Russell Burcombe, Steve Chan, Richard Simcock, Kunal Samanta, Fran Percival, Peter Barrett-Lee
-
Jai Dev Chandel, Nand Lal Singh
-
Zheng Yuan
-
Maxwell Omabe, Shahid Ahmed, Amer Sami, Yufeng Xie, Min Tao, Jim Xiang
-
Mohamed S. El Naschie